# A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Study · id `cardio:ct-nct06131372` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06131372](<https://clinicaltrials.gov/study/NCT06131372>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06131372

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 626 participants.

## Technical summary

Registry record NCT06131372. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2025-09-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 626 participants (enrolled count; ClinicalTrials.gov record NCT06131372, source copy `cardio:ctgov-nct06131372-2026-09-24`, retrieved 2026-10-26)
- Started: 2024-04-01 (actual) (ClinicalTrials.gov record NCT06131372, source copy `cardio:ctgov-nct06131372-2026-09-24`, retrieved 2026-10-26)
- Primary completion: 2025-09-24 (actual) (ClinicalTrials.gov record NCT06131372, source copy `cardio:ctgov-nct06131372-2026-09-24`, retrieved 2026-10-26)
- Completion: 2025-11-06 (actual) (ClinicalTrials.gov record NCT06131372, source copy `cardio:ctgov-nct06131372-2026-09-24`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; Canada; France; Greece; Hungary; India; Japan; Poland; Slovakia; Spain; Thailand (ClinicalTrials.gov record NCT06131372, source copy `cardio:ctgov-nct06131372-2026-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06131372-2026-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
- Condition: Chronic Kidney Disease
- Condition: Type 2 Diabetes
- Condition: Obesity
- Intervention (Drug): Cagrilintide
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 8b8c610e26cc97bb04fd86505b2fe7be7f011495c559c0a04167174f47214b4e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
